AVBPArriVent BioPharma, Inc.

Healthcare
$16.72-5.3% 1Y

The financials

ArriVent BioPharma, Inc. by the numbers

The next results filing is expected around Nov 9, 2026, the same week as a year ago.

ArriVent BioPharma, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$53M−$34Mn/a
Net income−$50M−$31Mn/a
Diluted EPS−$1.05−$0.90n/a
On our screens:Most shorted stocks

Biotechnology

The closest names by size in the same industry

Compare peers
ZBIO+3.7%
Zenas BioPharma, Inc.
SEPN+3.9%
Septerna, Inc.
IMCR+1.1%
Immunocore Holdings plc
ARDX+0.46%
Ardelyx, Inc.
MAZE+4.7%
Maze Therapeutics, Inc.
VIR+5.3%
Vir Biotechnology, Inc.